HomeMarketsEarningsLLY Plunges on Earnings & Weight Loss Drug Disappointment, Outlook Still Holds Optimism

LLY Plunges on Earnings & Weight Loss Drug Disappointment, Outlook Still Holds Optimism

"This market is priced for perfection," says Rebecca Walser, and it caused investors to see any red mark on Eli Lilly's (LLY) earnings as bearish. The stock plunged when its oral weight loss drug disappointed, though she believes there's more than enough market share for it to rebound. Andrew Wang agrees, adding that backing from the Trump administration "keeps me optimistic" on Eli Lilly's outlook.

Trading 360

07 Aug 2025

SHARE

ON AIR
4:30 pm
Market On Close
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
education
5:00 am
Liz Ann Live
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Market Overtime
REPLAY
8:00 am
Market Overtime
REPLAY
8:30 am
Market On Close
REPLAY
education
10:00 am
Schwab 2026 Outlook
REPLAY
11:00 am
Fast Market
REPLAY
12:00 pm
Next Gen Investing
REPLAY
education
1:00 pm
Liz Ann Live
REPLAY
1:30 pm
The Wrap
REPLAY
3:00 pm
Market Overtime
REPLAY
4:00 pm
Market Overtime
REPLAY
ON AIR
4:30 pm
Market On Close
REPLAY
education
6:00 pm
Schwab 2026 Outlook
REPLAY
7:00 pm
Fast Market
REPLAY
8:00 pm
Next Gen Investing
REPLAY
education
9:00 pm
Liz Ann Live
REPLAY
9:30 pm
The Wrap
REPLAY
11:00 pm
Market Overtime
REPLAY

Schwab Network's Newsletters

Daily insights for every investor